Sara Lonardi
Council
About
About
Sara Lonardi is Chief of the Oncology 3 Unit of Veneto Institute of Oncology (IOV) – IRCCS.
She obtained her Medical Degree in 2000 and her Oncology specialization in 2004, both from the University of Padova.
She is actively interested in the care of gastrointestinal cancer patients since 1998, and in 2013 became chief of the GI Cancer Unit, being involved in several international and national clinical trials as Principal Investigator. She was also Chief of Phase I Clinical Trial Unit at IOV-IRCCS.
She has published more than a two hundreds scientific articles in peer-reviewed journal dealing with colorectal cancer, gastrointestinal tumors and geriatric oncology.
Currently her interest is mainly focused on clinical and translational research in gastrointestinal cancers.
She is active member of Associazione Italiana di Oncologia Medica-AIOM, European Society of Medical Oncology-ESMO and American Society of Medical Oncology-ASCO, and member of the Steering Committee of the ACCENT DataBase
Publications
Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by GONO Foundation
J Clin Oncol. 2023 Aug 3
doi: 10.1200/JCO.23.00506 – PubMed ID: 37535876
Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials
Eur J Cancer. 2023 Aug;
doi: 10.1016/j.ejca.2023.05.001 – PubMed ID: 37301718
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study.
J Immunother Cancer. 2023 Apr
doi: 10.1136/jitc-2022-006633 – PubMed ID: 37085190
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials
Cancer Med. 2023 Apr
doi: 10.1002/cam4.5699 – PubMed ID: 36880426
Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs’ development
Br J Cancer. 2023 Mar
doi: 10.1038/s41416-023-02180-7 – PubMed ID: 36759721